Skip to main content

Association Between Proteinuria and Pregnancy Outcomes in Women With Preterm Pre-Eclampsia Undergoing Expectant Management: Secondary Analysis of Two Randomised Trials

Journal
BJOG : an international journal of obstetrics and gynaecology (Q1)
Published
18 September 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Amy van Rooyen, Lina Bergman, Henrik Imberg, Denise Sproul, Susan P Walker, Stephen Tong, et al.
PMID
42760504
DOI
10.1111/1471-0528.70335

Why clinicians should know about it

  • Picked for Obstetrics and Gynecology (paper of the day, 20 September 2026): Proteinuria levels predict latency and maternal outcomes in pre‑eclampsia
  • Picked for Neonatology (top studies of the week, 20 September 2026): Proteinuria in pre‑eclampsia, obstetric focus not neonatal respiratory

Abstract

OBJECTIVE: Evaluate whether proteinuria levels, in women undergoing expectant management for pre-eclampsia, are associated with pregnancy latency and adverse outcomes. DESIGN: Secondary analysis of data from two randomised trials. SETTING: Tygerberg Hospital, Cape Town, South Africa. POPULATION: Women undergoing expectant management for pre-eclampsia diagnosed between 26 and 32 weeks. METHODS: Latency was analysed using parametric time-to-event methods to estimate increases. Composite outcomes were assessed using Poisson regression. MAIN OUTCOME MEASURES: Pregnancy latency Composite adverse maternal or perinatal outcomes. RESULTS: Two hundred and ninety-one women were included. Women with < 3 g/24 h had a median prolongation of 15.3 days (interquartile range (IQR) 4.3 to 25.6), compared to 10.0 days (IQR 5.0 to 19.6) with proteinuria between 3 to 5 g/24 h; and 4.9 days (IQR 3.8 to 11.7) for those with ≥ 5 g/24 h. Increasing levels were also associated with increases in subsequent adverse composite maternal outcomes: 8.8% of women with < 3 g/24 h experienced maternal complications, compared to 16.1% with 3 to 5 g/24 h, and 27.9% with ≥ 5 g/24 h. There was no association with composite perinatal adverse outcomes. The sFlt-1/PIGF ratio performed slightly better in predicting latency (area under the receiver operating characteristic curve (AUC) 0.78 vs. 0.67) but similarly in predicting adverse composite maternal outcomes (AUC 0.67 vs. 0.64). Both had poor performance for predicting composite adverse perinatal outcomes (AUC 0.61 vs. 0.56). CONCLUSION: Levels of proteinuria strongly correlate with pregnancy latency and adverse maternal outcomes, but not perinatal outcomes, in women with pre-eclampsia undergoing expectant management. They perform similarly to angiogenic markers. Proteinuria levels may confer useful prognostic information to assist clinical decision-making.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.